Real-world Outcomes in Patients with EGFR Wildtype Non-squamous Locally Advanced/Metastatic NSCLC Receiving Second- or Third-Line Docetaxel: Pooled Analysis from LUMINATE-101
JOURNAL OF THORACIC ONCOLOGY(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined